Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-26 00:00:00 ET · period of report 2023-12-21 · accession 0001883850-23-000103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-26 | 2023-12-21+ | REGN | Fenimore Christopher R. | SVP Ctrl | S - Sale | $844.30 | -1,930 | 16.8K | -10% | -$1.63M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-21 | S | D | 1,224 | $844.09 | 17,070 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-21 | S | D | 456 | $843.79 | 18,294 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-22 | S | D | 250 | $846.27 | 16,820 | D | — | — |